AUTHOR=Xiong Anning , Nie Wei , Zhou Yan , Li Changhui , Gu Kai , Zhang Ding , Chen Shiqing , Wen Fengcai , Zhong Hua , Han Baohui , Zhang Xueyan TITLE=Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients JOURNAL=Frontiers in Immunology VOLUME=12 YEAR=2021 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.708558 DOI=10.3389/fimmu.2021.708558 ISSN=1664-3224 ABSTRACT=
The presence of comutations (co-mut+) in DNA damage response and repair (DDR) pathways was associated with improved survival for immune checkpoint inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). However, it remains unknown whether co-mut+ status could be a predictive biomarker for immunotherapy. We aimed to explore the predictive role of co-mut+ status in the efficacy of ICIs. A total of 853 NSCLC patients from OAK and POPLAR trials were included in the analyses for the relationship between co-mut status and clinical outcomes with atezolizumab treatment. In co-mut+ NSCLC patients, significantly prolonged progression-free survival (PFS) (